Adamax

Research Transparency Note: No peer-reviewed PubMed publications specific to Adamax as a named compound are available as of June 2026. The references below relate to the parent compound class (Semax/ACTH(4-10) analogue family) and the BDNF/TrkB receptor pharmacology context directly relevant to Adamax's proposed mechanism. Adamax-specific preclinical data are limited to vendor characterisation and non-peer-reviewed investigational reports. This limitation is a mandatory disclosure for any Adamax research programme.

What is Adamax?

Adamax is a synthetic nootropic neuropeptide derivative engineered as a structurally enhanced analogue of Semax (Met-Glu-His-Phe-Pro-Gly-Pro), itself a well-characterised heptapeptide analogue of the adrenocorticotropin fragment ACTH(4–10). Two pharmacokinetic modifications distinguish Adamax from the parent Semax: N-terminal acetylation (Ac-) to reduce exopeptidase-mediated proteolytic degradation, and a C-terminal adamantane (adamantyl) moiety derived from the P21 peptide scaffold to enhance lipophilicity, blood-brain barrier (BBB) penetration, and metabolic stability. The resultant sequence - Ac-Met-Glu-His-Phe-Pro-Gly-Pro-Adamantyl-Gly-NH₂ - retains the ACTH-derived neuropeptide core of Semax while addressing Semax's primary pharmacokinetic limitation: a plasma half-life of minutes due to peptidase degradation. The adamantane scaffold - a diamondoid hydrocarbon cage (C₁₀H₁₆) also present in CNS-active drugs amantadine and memantine - has been documented to improve BBB penetration and extend half-life in multiple CNS peptide research contexts by increasing compound lipophilicity above the threshold for passive membrane diffusion. Adamax is not FDA-approved for any use. It is supplied strictly for laboratory and preclinical research investigation of BDNF/TrkB signalling, MC4R pharmacology, and ACTH-derived neuropeptide structure-activity relationships.

This compound is not approved by the U.S. FDA for human or veterinary use. Intended for laboratory and research purposes only. Not a dietary supplement or consumer product. Availability restricted to qualified researchers and licensed laboratory institutions.

Chemical Properties

How Does Adamax Work?

MC4R / ACTH(4–10) Receptor System → BDNF/TrkB Axis: Adamax's proposed mechanism is grounded in the well-characterised pharmacology of its parent compound Semax, with the adamantane modification expected to amplify CNS penetration and duration of action rather than alter receptor engagement. The Semax core (Met-Glu-His-Phe-Pro-Gly-Pro) has been documented in peer-reviewed preclinical data to activate melanocortin receptor 4 (MC4R) with partial agonist activity, initiating a downstream cascade that upregulates brain-derived neurotrophic factor (BDNF) expression in the rat hippocampus. Dolotov et al. (2006, Brain Res, PMID 16996037) documented that a single intranasal Semax application (50 µg/kg) produced a 1.4-fold increase in BDNF protein levels, a 3-fold increase in BDNF exon III mRNA, and a 1.6-fold increase in TrkB tyrosine phosphorylation in the rat hippocampus - establishing BDNF/TrkB modulation as the mechanistic basis for Semax-class cognitive pathway activity in preclinical models. Adamax is investigated as an extension of this pharmacological platform with improved pharmacokinetic properties.

Adamantane Modification → Enhanced BBB Penetration and Half-Life: The C-terminal adamantyl group is a lipophilic diamondoid scaffold (C₁₀H₁₆, MW 136.23) that increases the overall lipophilicity of the Adamax molecule relative to unmodified Semax. In pharmaceutical chemistry, adamantane addition is a documented strategy for improving CNS bioavailability - the same scaffold is used in amantadine (antiviral/antiparkinsonian) and memantine (NMDA receptor antagonist for Alzheimer's disease) specifically to enhance BBB penetration. In the context of neuropeptide research, increased lipophilicity is associated with improved passive transcellular membrane diffusion, potentially enabling higher CNS concentrations from a given peripheral dose relative to the parent compound. N-terminal acetylation removes the free α-amino terminus, reducing susceptibility to aminopeptidase-mediated N-terminal cleavage and extending plasma stability.

TrkB Receptor Sensitisation in Hippocampal Models: BDNF elevation downstream of Semax/MC4R activation engages TrkB (tropomyosin receptor kinase B, NTRK2) - the primary BDNF receptor on hippocampal and cortical neurons. TrkB activation initiates MAPK/ERK and PI3K/Akt intracellular signalling cascades associated with synaptic plasticity, long-term potentiation (LTP), and dendritic spine density modulation in preclinical hippocampal cell models. Adamax is investigated as a research tool for probing TrkB sensitisation via BDNF pathway upregulation in hippocampal and cortical neuron cell models, in the context of understanding ACTH-derived peptide influences on neuroplasticity-relevant signalling cascades.

What are the Potential Research Applications of Adamax?

• BDNF/TrkB signalling pathway investigation: Adamax is investigated as a research tool for probing BDNF mRNA and protein expression changes downstream of melanocortin receptor activation in hippocampal cell culture models and rat brain tissue, extending the foundational Semax BDNF/TrkB research platform (Dolotov et al. 2006) with improved pharmacokinetic properties
• MC4R neuropeptide pharmacology: As a Semax-class partial MC4R agonist derivative, Adamax is investigated in structure-activity relationship research comparing the receptor pharmacology of N-terminal acetylation and C-terminal adamantane modification against unmodified Semax in melanocortin receptor-expressing cell model systems
• Adamantane peptide modification pharmacokinetics: The adamantane C-terminal modification of Adamax provides a research tool for investigating adamantyl conjugation effects on peptide BBB penetration efficiency, plasma half-life, and CNS tissue distribution in rodent pharmacokinetic model systems
• Neuroprotective pathway investigation: The Semax parent compound has been investigated for neuroprotective activity in ischaemic and excitotoxicity rodent models via BDNF/TrkB pathway upregulation. Adamax is investigated as an extended-half-life analogue for probing similar neuroprotective pathway activation in cell-based ischaemia models

Note: These findings are based on early-stage preclinical research on the parent compound Semax. No peer-reviewed published data specific to Adamax as a compound are available. Results are not consistent across all models, and data remains limited. All Adamax-specific research should be treated as a preliminary investigation pending independent replication.

What are the Potential Side Effects of Adamax?

• No Adamax-specific adverse signal data are documented in peer-reviewed literature. The following signals are extrapolated from the Semax parent compound class
• CNS stimulation signals: increased alertness, reduced sleep latency, and autonomic arousal consistent with MC4R activation have been anecdotally reported in non-clinical Semax-class compound use; research systems involving CNS-active endpoints should control for these pathway interactions
• The toxicological profile of Adamax is not established in any published peer-reviewed study. No chronic toxicity data exists. No human safety data has been established for research-grade Adamax at any concentration
• Data remains limited, and findings are not consistent across all model systems. The absence of documented adverse signals reflects the absence of peer-reviewed safety data, not confirmed safety

Risk & Handling

Handling Precautions

• Trained laboratory personnel only in a controlled laboratory environment
• PPE: nitrile gloves, laboratory coat, and eye protection required
• Reconstitute under aseptic conditions with sterile water or 0.1% acetic acid. Handle as a CNS-active neuropeptide research compound
• Institutional biosafety review recommended before initiating any CNS-active peptide research programme

Exposure Risks

• Risk Tier: MODERATE - Adamax is a CNS-active ACTH-derived neuropeptide. Potential MC4R activation upon unintended exposure may produce CNS pathway stimulation in biological systems. No human safety data. No published toxicological data. The absence of documented adverse signals reflects data scarcity, not established safety

Storage

• Store lyophilized at −20°C (long term) or 2–8°C (short term, days to weeks). Sealed, light-protected. Stable ≥24 months lyophilized
• Reconstituted solution: use within 30 days at 2–8°C. Avoid repeated freeze-thaw cycles

FAQs

How does Adamax differ from Semax?

Semax (Met-Glu-His-Phe-Pro-Gly-Pro) is the parent heptapeptide with a plasma half-life of minutes due to N-terminal aminopeptidase cleavage and general peptidase activity. Adamax adds N-terminal acetylation (blocking N-terminal proteolytic cleavage) and a C-terminal adamantane moiety (increasing lipophilicity and BBB penetration potential). These two modifications are designed to extend plasma and CNS residence time relative to Semax without altering the core ACTH(4–10)-derived BDNF/TrkB-activating sequence.

Does peer-reviewed literature exist specifically for Adamax?

No. Adamax is a vendor-coined designation for a specific N-acetyl Semax + adamantane modification. No peer-reviewed PubMed publications have been identified for Adamax as a named compound as of June 2026. The foundational mechanism references are for Semax (the parent compound), specifically Dolotov et al. 2006 (PMID 16996037) for BDNF/TrkB modulation. Researchers should treat Adamax as a preliminary research tool pending peer-reviewed compound-specific data.

What receptor does Adamax target?

Based on the Semax parent compound pharmacology, Adamax is proposed to act as a partial agonist at melanocortin receptor 4 (MC4R), initiating downstream BDNF upregulation and TrkB sensitisation in hippocampal models. The MC4R interaction for Semax itself has been characterised in published preclinical data. Whether the adamantane modification alters receptor binding affinity or selectivity has not been documented in peer-reviewed literature.

Storage requirements?

−20°C long term; 2–8°C short term. Sealed, light-protected. Reconstituted solution is stable for approximately 30 days at 2–8°C.

References

• Dolotov OV, Karpenko EA, Inozemtseva LS, et al. Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus. Brain Research. 2006;1117(1):54–60. https://pubmed.ncbi.nlm.nih.gov/16996037/
• Dolotov OV, Karpenko EA, Seredenina TS, et al. Semax, an analogue of adrenocorticotropin (4-10), binds specifically and increases levels of brain-derived neurotrophic factor protein in the rat basal forebrain. Journal of Neurochemistry. 2006;97(Suppl 1):82–86. https://pubmed.ncbi.nlm.nih.gov/16635254/

Note: These are the only peer-reviewed PubMed-indexed references that directly support the BDNF/TrkB mechanism attributed to Adamax - because Adamax inherits that mechanism entirely from the Semax core sequence. No Adamax-specific peer-reviewed paper exists.

Disclaimer: Adamax is exclusively for laboratory research purposes. RCDbio products are not intended to diagnose, prevent, treat, or cure any disease or medical condition.

The Food and Drug Administration has not evaluated the statements on our website. This product is not approved for human or veterinary use. Researchers must comply with all applicable local, state, and federal laws and regulations governing the purchase and use of research compounds. By purchasing, you agree to our Terms and Conditions. RCDbio reserves the right to refuse sales to unauthorized individuals.

ATTENTION: All RCDbio products are strictly for LABORATORY AND RESEARCH PURPOSES ONLY. They are not intended for human consumption, veterinary use, or any other non-research application. For queries, complaints, or support, contact support@rcdbio.co